Search Results

You are looking at 71 - 80 of 763 items for :

Clear All
Full access

Margaret Tempero

’s the problem? Of course, one of the gifts of aging is a greater chance of acquiring cancer. So we might expect to see a higher incidence of some cancers, and though we might be able to manage some of these cancers well, we need to include the management

Full access

Margaret Tempero

understand them am I truly able to care for their needs. Because I treat a disease that generally afflicts older adults, most of the time my patients' children are grown and have already reached many of the milestones that mark a productive life. But

Full access

Margaret Tempero

subsidies or tax breaks so you can afford insurance if you want it. Beyond those differences, though, it seems like simple economics; we ought to be able to find common ground and just fix it. My concern right now is that nothing will happen. That the

Full access

Margaret Tempero

one foot in front of the other, not knowing whether or how long they will survive, not knowing what is around the corner, and not being able to plan. Last year, I resolved to be a better oncologist. I resolved to care more, listen more, and

Full access

Margaret Tempero

HER2 amplification. I was thrilled. This was actionable and gave us another option down the road. So when the time came, after standard therapy stopped working, we were able to get both trastuzumab and pertuzumab. We started treatment, but it didn

Full access

Margaret Tempero

lives of most patients with chronic myelogenous leukemia, but not everyone who needed it was able to get the drug. I still remember hearing painful stories about young patients facing allogeneic bone marrow transplants who were refused the drug as an

Full access

Margaret Tempero

examinations are becoming less relevant in oncology with the increased use of imaging and other sophisticated diagnostics. Reimbursement for face time with a patient has improved, so there may be a way to make this economically feasible. But my being able to

Full access

William T. McGivney

announcements is that within 10 years, NCCN has been able to flip the decision-making system so that an organization of major cancer centers and their physician thought leaders, after review of scientific evidence, put forth recommendations about what

Full access

substantial clinical benefit with atypical radiographic responses. In this prospective, single-arm, phase II study of axitinib in R/M HNSCC of any site, patients must be able to swallow pills and cannot have evidence of lesions encasing major blood vessels (eg

Full access

site, patients must be able to swallow pills and cannot have evidence of lesions encasing major blood vessels (eg, carotid artery). Patients will be started on 5 mg of axitinib twice daily continuously, with subsequent dose escalation to 7 mg, and then